Rheumatoid arthritis: Guidelines for emerging therapies

American Journal of Managed Care

Volumn 7, Issue 6, 2001, Pages 617-626

  Blumberg, S N ^a   Fox, D A ^a  

^a Gralyn Health Associates Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; AURANOFIN; AUROTHIOGLUCOSE; CELECOXIB; CORTICOSTEROID; CYCLOSPORIN A; CYTOKINE; ETANERCEPT; GLUCOCORTICOID; GOLD SALT; HYDROXYCHLOROQUINE; HYDROXYCHLOROQUINE SULFATE; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 10; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PLACEBO; PREDNISONE; PROSTAGLANDIN SYNTHASE; RHEUMATOID FACTOR; ROFECOXIB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; UNINDEXED DRUG;

AUTOIMMUNE DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; DISABILITY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG USE; ECONOMIC EVALUATION; GASTROINTESTINAL SYMPTOM; GENETIC ANALYSIS; HEALTH CARE COST; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; IMMUNE RESPONSE; INCIDENCE; INJECTION SITE; JOINT DESTRUCTION; KIDNEY DISEASE; LEUKOPENIA; MANAGED CARE ORGANIZATION; META ANALYSIS; METABOLIC DISORDER; MODEL; MONOTHERAPY; PATHOGENESIS; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SYNTHESIS INHIBITION; RETINA DISEASE; REVIEW; RHEUMATOID ARTHRITIS; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADULT; ALGORITHMS; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYTOKINES; DISEASE MANAGEMENT; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; PRACTICE GUIDELINES; SIALOGLYCOPROTEINS; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 0034966795     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Epidemiology of rheumatoid arthritis
2. Epidemiological and clinical aspects relating to the variability of rheumatoid arthritis
3. The burden of rheumatoid arthritis: Facts and figures
4. The genetic contribution to the pathogenesis of rheumatoid arthritis
5. The genetics revolution and the assault on rheumatoid arthritis
6. 1958 revision of diagnostic criteria for rheumatoid arthritis
7. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
8. Rheumatoid arthritis: The clinical picture
9. Pathology of rheumatoid arthritis and associated disorders
10. The role of T cells in the immunopathogenesis of rheumatoid arthritis
11. Rheumatoid factor
12. The mortality of rheumatoid arthritis
13. Severe functional declines, work disability, and increased mortality in 75 rheumatoid arthritis patients studied over 9 years
14. Worldwide trends in the socioeconomic impact and long-term prognosis of rheumatoid arthritis
15. Preliminary criteria for clinical remission in rheumatoid arthritis
16. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo
17. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis
18. American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials
19. Disease-modifying antirheumatic drugs
20. The effectiveness of early treatment with "second line" antirheumatic drugs: A randomized, controlled study
21. The evolution of arthritis anti-inflammatory care: Where are we today?
22. Managing established rheumatoid arthritis
23. Guidelines for monitoring drug therapy in rheumatoid arthritis
24. Antimalarial drugs
25. Sulfasalazine
26. Methotrexate: Its use for the treatment of rheumatoid arthritis and other rheumatic disorders
27. Molecular therapeutics: Methotrexate and its mechanism of action
28. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: A double-blind, placebo-controlled trial
29. Methotrexate and emerging therapies
30. The efficacy and toxicity of combination therapy in rheumatoid arthritis: A meta-analysis
31. Triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine in patients with rheumatoid arthritis
32. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis
33. US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis
34. Gold and D-penicillamine
35. Cytokine blockage as a new strategy to treat rheumatoid arthritis: Inhibition of tumor necrosis factor
36. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis
37. Infliximab (chimeric anti-tumor necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III trial
38. Infliximab and methotrexate in the treatment of rheumatoid arthritis
39. Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial
40. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate
41. Anti-tumor necrosis factor-α monoclonal antibody therapy for rheumatoid arthritis
42. Outcomes for persons with rheumatoid arthritis with a rheumatologist versus a non-rheumatologist as the main physician for this condition
43. Trends in the use of disease modifying antirheumatic medications in rheumatoid arthritis, 1980-1995: Results from the National Ambulatory Medical Care Surveys
44. Early arthritis therapy: Rationale and current approach
45. Early referral, diagnosis, and treatment of rheumatoid arthritis: Evidence for changing medical practice
46. Guidelines for the management of rheumatoid arthritis